Seeking Alpha

FDA advisory panel votes to recommend rivaroxaban, the first serious contender to oral blood...

FDA advisory panel votes to recommend rivaroxaban, the first serious contender to oral blood clot treatment warfarin in decades. Johnson & Johnson (JNJ) has applied for use to treat orthapedic surgery patients, but Act II - stroke prevention - will be far more lucrative.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs